Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals.
Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals.
复制标题
DOI：
10.1186/s13722-024-00436-y
复制
发表时间：
2024-01-19
影响因子：
3.7
通讯作者：
Miller, William C.
中科院分区：
文献类型：
--
作者：
Franz, Berkeley;Dhanani, Lindsay Y.;Hall, O. Trent;Brook, Daniel L.;Fenstemaker, Cheyenne;Simon, Janet E.;Miller, William C.
丁丙诺啡是一种治疗阿片类药物使用障碍的高效药物，但卫生保健专业人员（HCP）未充分使用。阿片类药物使用障碍（MOUD）的错误信息可能是丁丙诺啡获得的一个重要障碍，但大多数实施策略旨在减少对阿片类药物使用障碍（OUD）患者的负面态度，而不是丁丙诺啡使用特定的错误信息。在这项研究中，我们评估了HCP认可丁丙诺啡相关错误信息的程度，以及这是否与向OUD患者提供护理的意愿相关。2022年9月至12月，我们调查了在俄亥俄州执业的HCP（n = 409）。我们的主要结果包括一个以前验证过的5项测量HCP治疗OUD患者意愿的指标，以及其他三项测量意愿的指标。我们的关键自变量是一项研究开发的5项措施，用于支持与丁丙诺啡相关的错误信息，该措施评估了丁丙诺啡在管理戒断症状和减少过量死亡方面的疗效，以及丁丙诺啡在实现缓解方面的作用。我们计算了描述性和双变量统计量，并拟合回归模型预测每个感兴趣的结果。平均而言，HCP在丁丙诺啡错误信息的复合指标上得分为2.34/5.00（SD = 0.80）。48.41%的受访者表示至少有一条错误信息。最受认可的项目是丁丙诺啡在减少过量死亡方面无效（M = 2.75，SD = 0.98），其使用可替代一种药物（M = 2.41，SD = 1.25）。HCP对丁丙诺啡错误信息的认可显著且负面地预测了与OUD患者一起工作的意愿（B = − 0.34; 95% CI − 0.46，− 0.21）;打算增加在该患者人群中花费的时间（B = − 0.36; 95% CI − 5.86，− 1.28）;获得X-豁免（OR = 0.54，95% CI 0.38，0.77）;以及打算获得X-豁免（OR：0.56; 95% CI：0.33−0.94）。错误信息在HCP中很常见，与治疗OUD患者的意愿较低相关。增加HCP使用MOUD的实施策略应特别抵制与丁丙诺啡相关的错误信息。临床试验注册：Clinicaltrials.gov，NCT 05505227。2022年8月17日注册，https://clinicaltrials.gov/ct2/show/NCT05505227
Buprenorphine is a highly effective medication for opioid use disorder that is underused by health care professionals (HCPs). Medications for opioid use disorder (MOUD) misinformation may be an important barrier to buprenorphine access, but most implementation strategies have aimed to reduce negative attitudes towards patients with opioid use disorder (OUD) rather than misinformation specific to buprenorphine use. In this study, we assessed the degree to which HCPs endorsed misinformation related to buprenorphine, and whether this is associated with willingness to provide care to patients with OUD. In September-December of 2022, we surveyed HCPs practicing in Ohio (n = 409). Our primary outcomes included a previously validated 5-item measure of HCP willingness to treat patients with OUD, and three other measures of willingness. Our key independent variable was a study-developed 5-item measure of endorsement of misinformation related to buprenorphine, which assessed beliefs in buprenorphine’s efficacy in managing withdrawal symptoms and reducing overdose deaths as well as beliefs about the role of buprenorphine in achieving remission. We computed descriptive and bivariable statistics and fit regression models predicting each outcome of interest. On average, HCPs scored 2.34 out of 5.00 (SD = 0.80) on the composite measure of buprenorphine misinformation. 48.41% of participants endorsed at least one piece of misinformation. The most endorsed items were that buprenorphine is ineffective at reducing overdose deaths (M = 2.75, SD =0 .98), and that its use substitutes one drug for another (M = 2.41, SD = 1.25). HCP endorsement of buprenorphine misinformation significantly and negatively predicted willingness to work with patients with OUD (b = − 0.34; 95% CI − 0.46, − 0.21); intentions to increase time spent with this patient population (b = − 0.36; 95% CI − 5.86, − 1.28); receipt of an X-waiver (OR = 0.54, 95% CI 0.38, 0.77); and intention to get an X-waiver (OR: 0.56; 95% CI: 0.33−0.94). Misinformation is common among HCPs and associated with lower willingness to treat patients with OUD. Implementation strategies to increase MOUD use among HCPs should specifically counter misinformation related to buprenorphine. Clinical Trial Registration: Clinicaltrials.gov, NCT05505227. Registered 17 August 2022, https://clinicaltrials.gov/ct2/show/NCT05505227
登录
查看更多内容
影响因子：
2
作者：
Hagemeier, Nicholas E.;Gray, Jeffrey A.;Pack, Robert P.
通讯作者：
Pack, Robert P.
影响因子：
3.1
作者：
Jamison, Robert N.;Scanlan, Elizabeth;Ross, Edgar L.
通讯作者：
Ross, Edgar L.
影响因子：
3.5
作者：
Keller, Craig E.;Ashrafioun, Lisham;Blondell, Richard D.
通讯作者：
Blondell, Richard D.
DOI：
10.1016/j.ssmqr.2022.100161
发表时间：
2022-12-01
期刊：
SSM-QUALITATIVE RESEARCH IN HEALTH
影响因子：
--
作者：
Madden, Erin F.;Barker, Kristin K.;Sulzer, Sandra H.
通讯作者：
Sulzer, Sandra H.
污名对阿片类药物使用障碍，阿片类药物治疗和政策患者的影响。
影响因子：
1.8
作者：
Cheetham A;Picco L;Barnett A;Lubman DI;Nielsen S
通讯作者：
Nielsen S